familymednews.com
During development in the womb, immune cells called macrophages go to the kidneys, and they remain there for life. Understanding the possible healing role for these macrophages after kidney damage may be crucial to helping treat patients who suffer acute kidney injury. Acute kidney injury, or AKI, is a devastating condition that develops in two-thirds of critically ill patients, and […]
Continue reading »
(HealthDay)—A task force to investigate a rising number of cases of a rare polio-like disease among children in the United States has been created by the U.S. Centers for Disease Control and Prevention. The task force on acute flaccid myelitis (AFM) will include scientific, medical, and public health experts who will attempt to identify the cause of the disease and […]
Continue reading »
Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and researchers at St. Jude Children’s Research Hospital have discovered that this problem starts during remission-induction treatment and suggests that early intervention should be considered. Chemotherapy drugs to treat ALL contribute to myriad problems, one of which is an increased risk of becoming overweight or obese. And because patients […]
Continue reading »
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs […]
Continue reading »
Mechanical thrombectomy is an increasingly important therapy for acute stroke that can also benefit the very old – assuming a careful selection of patients and risk assessment. This is a finding of a Portuguese study presented at the 4th Congress of the European Academy of Neurology (EAN) in Lisbon. For several years now, the endovascular thrombectomy has been a way […]
Continue reading »
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. The multi-center Phase I trial, led by researchers at The University of Texas MD Anderson Cancer Center, was designed to determine ivosidenib’s safety and […]
Continue reading »
Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein […]
Continue reading »
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that comprises 1 percent of all new cancer cases and almost 2 percent of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20 percent. Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore […]
Continue reading »
In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and […]
Continue reading »